復星醫藥:BioNTech將向中國大陸供應不少於1億劑新冠疫苗產品
uSMART盈立智投12月16日消息,週三港股盤前,復星醫藥發佈公告稱,,於2020年12月15日,BioNTech Manufacturing GmbH,爲BioNTech的附屬公司(「BioNTech Manufacturing」)、復星醫藥產業及BioNTech就有關BioNTech Manufacturing向其於中國大陸供應新冠疫苗產品訂立供貨協議(「供貨協議」)。
根據供貨協議,在新冠疫苗產品獲得中國大陸上市批準且復星醫藥產業根據供應協議下達相應訂單的情況下,BioNTechManufacturing承諾於2021年向中國大陸供應不少於1億劑新冠疫苗產品。
點擊可跳轉閱讀《復星醫藥自願公告》原文件PDF。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.